Investigators from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) will discuss the latest findings from the study during the Scientific Sessions symposium DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?! The symposium begins at 4:00 p.m. CT Saturday, June 13.

DAPA-HF was designed to evaluate the effect of dapagliflozin, a sodium-glucose transporter 2 (SGLT2) inhibitor, on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction (HFrEF).

Initial results from the study published in 2019 indicated that the risk of worsening heart failure or death from cardiovascular causes was lower among patients with HFrEF who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes.

“We observed that dapagliflozin had modest effects on A1C, weight, and blood pressure during the trial. The effect on A1C in non-diabetic participants was actually negligible,” said Silvio E. Inzucchi, MD, Professor of Medicine (Endocrinology) at Yale School of Medicine and Medical Director of the Yale Diabetes Center. “The SGLT2 inhibitor also proved to be very safe, with no increase in rates of hypoglycemia, volume-related adverse events, or acute kidney injury.”

During the symposium, Dr. Inzucchi will review the metabolic and safety aspects of DAPA-HF. He will also present new data about the impact of dapagliflozin on the incidence of type 2 diabetes in non-diabetic study participants, which represents a significant new finding in the SGLT2 inhibitor class, he said.

In other presentations, John J.V. McMurray, MD, Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, will review the background and main cardiovascular outcomes of the study; Mikhail N. Kosiborod, MD, Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael and Marlys Haverty Cardio Metabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, will discuss patient-centered outcomes; and Jeffrey M. Testani, MD, Associate Professor Term and Director of Heart Failure Research, Cardiovascular Medicine, at Yale School of Medicine, will review the implications for clinical care and possible directions of future study.